HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hother-Nielsen, O. Articles by Pedersen, O. Search for Related Content PubMed PubMed Citation Articles by Hother-Nielsen, O. Articles by Pedersen, O.

Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes

Abstract. Nine obese patients with Type II diabetes mellitus were examined in a double-blind cross-over study. Metformin 0.5 g trice daily or placebo were given for 4 weeks. At the end of each period fasting and day-time postprandial values of plasma glucose, insulin, C-peptide and lactate were determined, and in vivo insulin action was assessed using the euglycemic clamp in combination with [3-³H]glucose tracer technique. Metformin treatment significantly reduced mean day-time plasma glucose levels (10.2 ± 1.2 vs 11.4 ± 1.2 mmol/l, P< 0.01) without enhancing mean day-time plasma insulin (43 ± 4 vs 50 ± 7 mU/l, NS) or C-peptide levels (1.26 ± 0.12 vs 1.38 ± 0.18 nmol/l, NS). Fasting plasma lactate was unchanged (1.57 ± 0.16 vs 1.44 ± 0.11 mmol/l, NS), whereas mean day-time plasma lactate concentrations were slightly increased (1.78 ± 0.11 vs 1.38 ± 0.11 mmol/l, P< 0.01). The clamp study revealed that metformin treatment was associated with an enhanced insulin-mediated glucose utilization (370 ± 38 vs 313 ± 33 mg · m^–2 · min^–1, P< 0.01), whereas insulin-mediated suppression of hepatic glucose production was unchanged. Also basal glucose clearance was improved (61.0 ± 5.8 vs 50.6 ± 2.8 ml · n^–2 · min^–1,, P< 0.05), whereas basal hepatic glucose production was unchanged (81 ± 6 vs 77 ± 4 mg · m^–2 · min^–1, NS). Conclusions: 1) Metformin treatment in obese Type II diabetic patients reduces hyperglycemia without changing the insulin secretion. 2) The improved glycemic control during metformin treatment was associated with an enhanced insulin-mediated glucose utilization, presumably in skeletal muscle, whereas no effect could be demonstrated on hepatic glucose production.

This article has been cited by other articles:

				K. Zhou, L. A. Donnelly, C. H. Kimber, P. T. Donnan, A. S.F. Doney, G. Leese, A. T. Hattersley, M. I. McCarthy, A. D. Morris, C. N.A. Palmer, et al. Reduced-Function SLC22A1 Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: A GoDARTS Study Diabetes, June 1, 2009; 58(6): 1434 - 1439. [Abstract] [Full Text] [PDF]

				R. Basu, P. Shah, A. Basu, B. Norby, B. Dicke, V. Chandramouli, O. Cohen, B. R. Landau, and R. A. Rizza Comparison of the Effects of Pioglitazone and Metformin on Hepatic and Extra-Hepatic Insulin Action in People With Type 2 Diabetes Diabetes, January 1, 2008; 57(1): 24 - 31. [Abstract] [Full Text] [PDF]

				N. Fujii, N. Jessen, and L. J. Goodyear AMP-activated protein kinase and the regulation of glucose transport Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E867 - E877. [Abstract] [Full Text] [PDF]

				A. Natali, S. Baldeweg, E. Toschi, B. Capaldo, D. Barbaro, A. Gastaldelli, J. S. Yudkin, and E. Ferrannini Vascular Effects of Improving Metabolic Control With Metformin or Rosiglitazone in Type 2 Diabetes Diabetes Care, June 1, 2004; 27(6): 1349 - 1357. [Abstract] [Full Text] [PDF]

				S. R. Salpeter, E. Greyber, G. A. Pasternak, and E. E. Salpeter Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis Arch Intern Med, November 24, 2003; 163(21): 2594 - 2602. [Abstract] [Full Text] [PDF]

				Z. Zhang and J. Radziuk Inverse relationship between peripheral insulin removal and action: studies with metformin Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1240 - E1248. [Abstract] [Full Text] [PDF]

				S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring Pathophysiology and Pharmacological Treatment of Insulin Resistance Endocr. Rev., December 1, 2000; 21(6): 585 - 618. [Abstract] [Full Text]

				S. D. Wise, M. F. Nielsen, P. E. Cryer, and R. A. Rizza Overnight Normalization of Glucose Concentrations Improves Hepatic But Not Extrahepatic Insulin Action in Subjects with Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2461 - 2469. [Abstract] [Full Text]

				R. Bressler and D. G. Johnson Pharmacological Regulation of Blood Glucose Levels in Non--Insulin-Department Diabetes Mellitus Arch Intern Med, April 28, 1997; 157(8): 836 - 848. [Abstract] [PDF]